Kazia Therapeutics (KZIA) Cash & Equivalents (2009 - 2025)

Kazia Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $45.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 2175.82% year-over-year to $45.6 million; the trailing twelve-month figure through Dec 2025 stood at $45.6 million (up 2175.82% YoY), and the FY2025 full-year result was $2.8 million, up 154.81% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $45.6 million, up from $2.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $45.6 million in Q4 2025, with the low at $1.1 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $9.8 million across 5 years, with a median of $3.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 75.18% — and 2025, when it soared 2175.82%.
• Kazia Therapeutics' Cash & Equivalents stood at $11.1 million in 2021, then slumped by 73.93% to $2.9 million in 2022, then dropped by 19.6% to $2.3 million in 2023, then fell by 13.59% to $2.0 million in 2024, then soared by 2175.82% to $45.6 million in 2025.
• The last three Cash & Equivalents figures came in at $45.6 million (Q4 2025), $2.8 million (Q2 2025), and $2.0 million (Q4 2024), per Business Quant data.